The prognostic impat of urokinase type plasminogen activator receptor in colorectal cancer

2000 ◽  
Vol 118 (4) ◽  
pp. A511
Author(s):  
L.N Herszenyi ◽  
F. Farinati ◽  
M. Plebani ◽  
G. Istvan ◽  
P. Carraro ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Plasminogen Activator ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Plasminogen Activator Receptor

scholarly journals Antigen levels of urokinase-type plasminogen activator receptor and its gene polymorphism related to microvessel density in colorectal cancer.

2008 ◽  
Vol 55 (2) ◽  
pp. 357-363
Author(s):  
Karolina Przybylowska ◽  
Janusz Szemraj ◽  
Andrzej Kulig ◽  
Adam Dziki ◽  
Joanna Ulanska ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Plasminogen Activator ◽  
Microvessel Density ◽  
Repeat Polymorphism ◽  
Urokinase Plasminogen Activator Receptor ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Its Gene ◽  
Plasminogen Activator Receptor ◽  
Colorectal Cancer Patients

We determined the distribution of genotypes and frequencies of alleles of the (CA)(n) repeat polymorphism in intron 3 of the urokinase plasminogen activator receptor (uPAR) gene, uPAR antigen levels and microvessel density (MVD) in tumour and distant mucosa samples from 52 patients with colorectal cancer. The uPAR level was higher for patients with high MVD comparing to patients with lower MVD which may suggest that uPAR can be correlated with progression of colorectal cancer. The significant relationship between the high MVD and uPAR antigen level appeared to be independent of the (CA)(n) repeat polymorphism because no differences in the level of uPAR antigen between carriers of alleles were found. The received results, indicate that uPAR might be considered as a target in colorectal cancer patients' therapy.

scholarly journals Urokinase‐type plasminogen activator receptor (uPAR) on tumor‐associated macrophages is a marker of poor prognosis in colorectal cancer

2014 ◽  
Vol 3 (4) ◽  
pp. 855-864 ◽  
Author(s):  
Martin Illemann ◽  
Ole Didrik Laerum ◽  
Jane Preuss Hasselby ◽  
Tine Thurison ◽  
Gunilla Høyer‐Hansen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Plasminogen Activator ◽  
Poor Prognosis ◽  
Tumor Associated Macrophages ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Plasminogen Activator Receptor

scholarly journals The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer

Cancers ◽  
2021 ◽  
Vol 13 (20) ◽  
pp. 5100
Author(s):  
Kristian Blomberg ◽  
Torben F. Hansen ◽  
Claus L. Brasen ◽  
Jeppe B. Madsen ◽  
Lars H. Jensen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Plasminogen Activator ◽  
Treatment Cycle ◽  
Performance Status ◽  
Progression Free Survival ◽  
Supar Level ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Plasminogen Activator Receptor ◽  
And Performance

The soluble urokinase-type plasminogen activator receptor (suPAR) is prognostic for overall survival (OS) in colorectal cancer (CRC). Our study explored the association between baseline suPAR and OS and progression-free survival (PFS) in metastatic CRC (mCRC). It is also the first study to explore the association between the initial change in suPAR level and OS, PFS and the first CT response evaluation. The study included 132 patients with mCRC treated with chemotherapy (FOLFIRI) with or without an EGFR-inhibitor. Blood samples were drawn before the first treatment cycle and in between the first and second treatment cycle. suPAR levels were determined using an ELISA assay. Using the Kaplan-Meyer method, we demonstrated a significantly shorter OS for patients with suPAR levels above the median (HR = 1.79, 95%CI = 1.10–2.92, p = 0.01). We also showed association between plasma suPAR level, gender and performance status (PS). However, we could not show any association with PFS, and analysis on the change in suPAR level provided no significant results. The results showing association between baseline suPAR and OS are in line with previous findings.

Urokinase type plasminogen activator and inhibitor type-1 plasma levels in colorectal cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A599-A600 ◽  
Author(s):  
L HERSZENYI ◽  
F FARINATI ◽  
G ISTVAN ◽  
M PAOLI ◽  
G ROVERONI ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Plasminogen Activator ◽  
Plasma Levels ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Inhibitor Type
Sign in / Sign up

Export Citation Format

Share Document